AARTIPHARMBSEAarti Pharmalabs LtdMinimalNeutral
Announced Tue, 26 May · 16:45 IST

Annual Secretarial Compliance Report for the Financial Year 2025-26

AARTIPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-6.9%1-day move
₹694.65
prior close
₹694.60
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.5-1.1-0.8-1.3-6.9-7.6-8.4-10.5-7.6-12.5-5.1-2.4-1.7
Up moveDown movePending
AI summary

Aarti Pharmalabs Limited has filed its Annual Secretarial Compliance Report for FY 2025-26, certified by practicing company secretaries Mehta & Mehta. The report covers compliance with key SEBI regulations including LODR, Prohibition of Insider Trading, Depositories, and Employee Benefits. The company achieved compliance across most areas with zero material violations reported. One minor procedural observation was noted: the company obtained prior Audit Committee approval for all related party transactions except one amounting to Rs. 5.16 lakhs, which was ratified subsequently. All other compliance areas including secretarial standards, website disclosures, director disqualification checks, performance evaluations, and insider trading norms showed full compliance.

Likely market impact

Overall positive for shareholders — the company maintains strong regulatory compliance with only a trivial procedural lapse in related party transaction approval. The Rs. 5.16 lakh transaction represents a negligible amount relative to company operations, and the subsequent ratification indicates proper governance oversight.